Novartis/Schering AG Re-Evaluating PTK/ZK Development Due To Low Probability Of Survival Benefit

Firms plan to reconsider NDA submission strategy after interim analysis of CONFIRM-2 trial suggests PTK/ZK 787 is unlikely to yield survival benefit in second-line metastatic colorectal cancer.